heb nasal

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
heb nasal
Generic name
PHENYLEPHRINE HYDROCHLORIDE
Manufacturer
H E B
Product type
HUMAN OTC DRUG
SPL set ID
2cf319cc-bb49-4b7d-bb08-e3346b4a78d4
SPL ID
3348c9be-b3f8-4567-bffd-289c54085287
Version
8
Effective date
2026-09-18
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:17
Harmonized routes table
Harmonized routes
NASAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings Ask a doctor before use if you have • heart disease • high blood pressure • thyroid disease • diabetes • trouble urinating due to an enlarged prostate gland When using this product • do not exceed recommended dosage • do not use for more than 3 days. use only as directed. • temporary discomfort such as burning, stinging, sneezing or an increase in nasal discharge may occur • the use of this container by more than one person may spread infection • frequent or prolonged use may cause nasal congestion to recur or worsen Stop use and ask a doctor if symptoms persist. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222).

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.